Literature DB >> 7786010

In vitro activity of a new fluoroquinolone, CP-99,219, against strains of Neisseria gonorrhoeae.

J S Knapp1, S W Neal, M C Parekh, R J Rice.   

Abstract

The susceptibilities of 216 strains of Neisseria gonorrhoeae to a new fluoroquinolone, CP-99,219 were determined. For strains for which the MICs of ciprofloxacin were < or = 0.06 microgram/ml, the MICs at which 90% of the isolates are inhibited (MIC90s) of CP-99,219, ciprofloxacin, and ofloxacin were 0.008, 0.015, and 0.03 microgram/ml, respectively. For strains for which the MICs of ciprofloxacin were 0.125 to 0.5 microgram/ml, the MIC90s of CP-99,219, ciprofloxacin, and ofloxacin were 0.06, 0.25, and 0.5 microgram/ml, respectively. For strains for which the MICs of ciprofloxacin and ofloxacin were 2.0 micrograms/ml, the MIC of CP-99,219 was 0.25 microgram/ml.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7786010      PMCID: PMC162668          DOI: 10.1128/AAC.39.4.987

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Failure of 500 mg ciprofloxacin therapy in male urethral gonorrhoea.

Authors:  J W Tapsall; T R Shultz; R Lovett; R Munro
Journal:  Med J Aust       Date:  1992-01-20       Impact factor: 7.738

2.  Ciprofloxacin resistance in gonococci.

Authors:  A E Jephcott; A Turner
Journal:  Lancet       Date:  1990-01-20       Impact factor: 79.321

3.  Decreased susceptibility of Neisseria gonorrhoeae to ciprofloxacin.

Authors:  W R Gransden; C A Warren; I Phillips; M Hodges; D Barlow
Journal:  Lancet       Date:  1990-01-06       Impact factor: 79.321

4.  Persistence of Neisseria gonorrhoeae strains with decreased susceptibilities to ciprofloxacin and ofloxacin in Cleveland, Ohio, from 1992 through 1993.

Authors:  J S Knapp; J A Washington; L J Doyle; S W Neal; M C Parekh; R J Rice
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

5.  Susceptibility of Neisseria gonorrhoeae associated with pelvic inflammatory disease to cefoxitin, ceftriaxone, clindamycin, gentamicin, doxycycline, azithromycin, and other antimicrobial agents.

Authors:  R J Rice; J S Knapp
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

6.  Sentinel surveillance for antimicrobial resistance in Neisseria gonorrhoeae--United States, 1988-1991. The Gonococcal Isolate Surveillance Project Study Group.

Authors:  R J Gorwitz; A K Nakashima; J S Moran; J S Knapp
Journal:  MMWR CDC Surveill Summ       Date:  1993-08-13

7.  Emerging in vitro resistance to quinolones in penicillinase-producing Neisseria gonorrhoeae strains in Hawaii.

Authors:  J S Knapp; R Ohye; S W Neal; M C Parekh; H Higa; R J Rice
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

8.  Antimicrobial susceptibilities of Neisseria gonorrhoeae strains representing five distinct resistance phenotypes.

Authors:  R J Rice; J S Knapp
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

9.  Antibiotic susceptibility survey of Neisseria gonorrhoeae in Thailand.

Authors:  T E Clendennen; P Echeverria; S Saengeur; E S Kees; J W Boslego; F S Wignall
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

  9 in total
  4 in total

1.  In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone.

Authors:  M Takahata; J Mitsuyama; Y Yamashiro; M Yonezawa; H Araki; Y Todo; S Minami; Y Watanabe; H Narita
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 2.  Trovafloxacin.

Authors:  M Haria; H M Lamb
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

3.  Dose-ranging study of CP-99,219 (trovafloxacin) for treatment of uncomplicated gonorrhea.

Authors:  E W Hook; G B Pinson; C J Blalock; R B Johnson
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

4.  Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography.

Authors:  A J Fischman; J W Babich; A A Bonab; N M Alpert; J Vincent; R J Callahan; J A Correia; R H Rubin
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.